

Institut für Urologie und Andrologie

Institutsleitung: Prim. Univ.-Prof. DDr. hc Shahrokh F. Shariat

Wissenschaftliche Referate 2022:

Univ.Prof.Dr. Shahrokh Shariat

Invited lecturer , Philadelphia University, Philadelphia, Pennsylvania <i>Quality indicators in UTUC</i>	2/17/2022
Invited lecturer , Interdisziplinäre T.U.M.O.R. Tage <i>ASCO-GU Updates Urothelial Carcinoma</i>	3/12/2022
Invited lecturer , PhD students, Semmelweis University Budapest, Hungary <i>Tips for a successful career as physician scientist</i>	3/25/2022
Invited lecturer , Winthertur hospital, Switzerland <i>Treatment of locally advanced and metastatic bladder cancer</i>	4/4/2022
Invited lecturer , Österreichische Gesellschaft für klinische Pathologie und Molekularpathologie, Abteilung der Internationalen Akademie für Pathologie, Vienna <i>Ohne Pathologie keine Therapie: aus der Sicht des Urologen</i>	30/4/2022
Invited lecturer , Iranian Urologic Association, Iran, Online <i>Perioperative systemic therapy for clinically localized MIBC Discussion of muscle invasive case</i>	19/5/2022
Invited lecturer , ESU course at the 7 th Baltic Meeting with the EAU, Vilnius, Lithuania <i>Local therapy for metastatic prostate cancer</i> <i>Prognostic and predictive factors, pathology- Upper tract urothelial carcinoma</i> <i>Treatment of localized high risk (invasive) and metastatic upper tract urothelial carcinoma</i>	5/30/2022
Invited lecturer , Al Ahliya University, Amman, Jordan <i>How to build a research affine culture and infrastructure</i>	6/19/2022
Invited lecturer , Brazilian Urologic Oncology Society, Sao Paulo, Brazil <i>Quality criteria for good UTUC care</i> <i>The future of perioperative systemic therapy for muscle invasive bladder cancer</i>	6/26/2022
Invited lectures and chair , 36 th Annual EAU Congress <i>Controversies in onco-urology: Young surgeons should learn open surgery in the robotic era</i> <i>Perioperative treatment of urothelial cancer in 2022: adjuvant therapy</i> <i>Lecture: Accurate risk stratification and prognostic factors</i> <i>Lecture: Treatment of advanced and metastatic disease</i>	7/2/2022
Invited lecturer , European Society of Radiology Annual Meeting, Vienna, Austria <i>Management of bladder cancer: from bench to bedside</i>	7/15/2022
Invited lecturer , Methods in clinical cancer research 2022, Salzburg, Austria <i>Tips for a successful career as clinician scientist</i> <i>How to write a paper</i>	9/15/2022

Invited lecturer , Swiss Urological Society, Bern, Switzerland <i>Quality indicators of upper tract urothelial carcinoma</i>	10/5/2022
Invited lecturer , 2 nd Faculty of the Charles University, Prag, Czech Republic <i>Metastatic urothelial carcinoma in 2022</i> <i>Career development: science as a motor for success and joy</i>	
Course director and invited lecturer , Cancer Update CCC Vienna, Vienna, Austria <i>Hodenkrebs: wo kommen wir her und wo gehen wir hin</i>	11/15/2022
Invited lecturer , Stift Göttweig, Göttweig, Austria <i>Offene Chirurgie: warum sie heute noch notwendig ist</i>	18/11/2022
Invited lecturer , Fortbildung des Berufsverband der Urologen, Vienna, Austria <i>Intravesikale Therapie für nicht-muskel-invasives Blasenkarzinom</i>	11/24/2022
Invited lecturer , 12 th Shanghai Genitourinary Oncology International Symposium <i>Challenges and unmet needs in metastatic hormone sensitive prostate cancer</i> <i>Update on metastatic urothelial carcinoma</i>	11/26/2022
Invited lecturer , 5te Internationales Symposium Uro-Onkologie, Magdeburg, Germany <i>Robotic versus open radical cystectomy: the data and the reality</i>	12/2/2022

Assoc.Prof.Priv.Doz.Dr.Harun Fajkovic

AK Laparoskopie – Semi-Live Symposium 3 Tricks für die laparoskopische Nierenchirurgie	09/16/22
Invited Lecturer: Onkologisch – laparoskopisch und roboterchirurgisches Herbstsymposium <i>Organerhaltende OP-Strategien</i>	11/19/22
Workshop Laparoskopie am Schwein	12/01/22
Invited Lecturer: Annual Meeting of the Slovak Urological Society, Bratislava <i>Update NMIBC</i>	06/22
Invited Lecturer: Prostate Cancer Masterclass Vienna <i>Pelvic LND. When, How and Why?</i>	21/06/22
Invited Lecturer: 8th Slovenian urological Congress, Ljubljana <i>Update NMIBC</i>	09/22
Invited Lecturer: Urology Symposium – New Horizons in Urology, Split <i>Management of NMIBC</i>	10/22

Assoc.Prof.Priv.Doz.Dr. Christian Seitz

Invited Lecturer FBK Webinar <i>Hat die Fusionsbiopsie der Prostata noch eine Alternative?</i>	04/20/22
AK Laparoskopie – Semi-Live Symposium <i>Nerve Sparing</i>	09/16/22

Invited Lecturer: FBK Webinar <i>Nierenchirurgie in Österreich. Offen vs. Laparoskopisch</i>	04/20/22
AK Laparoskopie – Semi-Live Symposium Nierenbeckenplastik	09/16/22
Onkologisch – laparoskopisch und roboterchirurgisches Herbstsymposium <i>Operative Techniken beim AML</i>	11/19/22
Invited Lecturer: FBK Webinar <i>Angiomyolipome: was gibt es neues in der Therapie?</i>	12/14/22
Workshop Laparoskopie am Schwein	12/01/22

Wissenschaftliche Publikationen 2022:

- 1: Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Motlagh RS, Laukhtina E, Rajwa P, Deimling MV, Bianchi A, Pallauf M, Majdoub M, Pradere B, Moschini M, Karakiewicz PI, Teoh JY, Miki J, Kimura T, Shariat SF. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer. *Eur Urol Focus*. 2022 Dec 12:S2405-4569(22)00287-5. doi: 10.1016/j.euf.2022.12.003. Epub ahead of print. PMID: 36517409.
- 2: Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J, Shariat SF, Choueiri T, Müller G, McGregor B, Chang SL, Trinh QD, Mossanen M. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. *Clin Genitourin Cancer*. 2022 Nov 24:S1558-7673(22)00250-6. doi:10.1016/j.clgc.2022.11.015. Epub ahead of print. PMID: 36517393.
- 3: von Deimling M, Laukhtina E, Pradere B, Pallauf M, Klemm J, Fisch M, Shariat SF, Rink M. Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges-a narrative review. *Transl Androl Urol*. 2022 Nov;11(11):1598-1610. doi: 10.21037/tau-22-463. PMID: 36507477.
- 4: Kawada T, Yanagisawa T, Araki M, Pradere B, Shariat SF. Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis. *Curr Opin Urol*. 2022 Dec 26. doi: 10.1097/MOU.0000000000001065. Epub ahead of print. PMID: 36482766.
- 5: Rahman SN, Lokeshwar SD, Syed JS, Javier-Desloges JF, Press BH, Choksi AU, Rajwa P, Pradere B, Ploussard G, Kim JW, Monaghan TF, Renzulli JR, Shariat SF, Leapman MS. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. *Urol Oncol*. 2022 Dec 5:S1078-1439(22)00317-9. doi: 10.1016/j.urolonc.2022.09.008. Epub ahead of print. PMID: 36481253.

6: Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Sari Motlagh R, Laukhtina E, Rajwa P, von Deimling M, Bianchi A, Pallauf M, Majdoub M, Pradere B, Abufaraj M, Moschini M, Karakiewicz PI, Iwatani K, Miki J, Kimura T, Shariat SF.

Oncologic Impact of Cystoscopic Findings in Non-Muscle Invasive Bladder Cancer: A Meta-analysis. *BJU Int.* 2022 Dec 7.

doi: 10.1111/bju.15944. Epub ahead of print. PMID: 36479820.

7: Pallauf M, D'Andrea D, König F, Laukhtina E, Yanagisawa T, Rouprêt M, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Fujita K, Boorjian SA, Potretzke AM, Mari A, Roumiguié M, Antonelli A, Bianchi A, Khene ZE, Sfakianos JP, Jamil M, Boormans JL, Raman JD, Grossmann NC, Breda A, Heidenreich A, Del Giudice F, Singla N, Shariat SF, Pradere B.

Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients - A Multicenter, Retrospective, Observational Study.

J Urol. 2022 Dec 7:101097JU00000000000003085.

doi: 10.1097/JU.0000000000003085. Epub ahead of print. PMID: 36475808.

8: Kawada T, Laukhtina E, Quhal F, Yanagisawa T, Rajwa P, Pallauf M, von Deimling M, Bianchi A, Pradere B, Fajkovic H, Enikeev D, Gontero P, Rouprêt M, Seisen T, Araki M, Shariat SF.

Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis.

Eur Urol Focus. 2022 Nov 30:S2405-4569(22)00275-9.

doi: 10.1016/j.euf.2022.11.016. Epub ahead of print. PMID: 36463089.

9: Bianchi A, von Deimling M, Pallauf M, Yanagisawa T, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Majdoub M, Motlagh RS, Pradere B, Karakiewicz PI, Cerruto MA, Antonelli A, Shariat SF.

Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.

Expert Opin Pharmacother. 2022 Nov 29:1-19.

doi: 10.1080/14656566.2022.2150966. Epub ahead of print. PMID: 36440477.

10: Laukhtina E, Kawada T, Quhal F, Yanagisawa T, Rajwa P, von Deimling M, Pallauf M, Bianchi A, Majdoub M, Enikeev D, Fajkovic H, Teoh JY, Rouprêt M, Gontero P, Shariat SF.

Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis.

Eur Urol Focus. 2022 Nov 22:S2405-4569(22)00264-4.

doi: 10.1016/j.euf.2022.11.014. Epub ahead of print. PMID: 36428210.

11: Vartolomei L, Schmidinger M, Vartolomei MD, Shariat SF.

Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review.

J Clin Med. 2022 Oct 28;11(21):6383.

doi: 10.3390/jcm11216383. PMID: 36362610; PMCID: PMC9657659.

12: Katayama S, Pradere B, Grossman NC, Potretzke AM, Boorjian SA, Ghoreifi A, Daneshmand S, Djaladat H, Sfakianos JP, Mari A, Khene ZE, D'Andrea D, Hayakawa N, Breda A, Fontana M, Fujita K, Antonelli A, van Doeveren T, Steinbach C, Mori K, Laukhtina E, Rouprêt M, Margulis V, Karakiewicz PI, Araki M, Compérat E, Nasu Y, Shariat SF.

Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy.

Int J Urol. 2022 Nov 9.

doi: 10.1111/iju.15061. Epub ahead of print. PMID: 36349904.

13: Vartolomei MD, Remzi M, Fajkovic H, Shariat SF.

Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review.

J Clin Med. 2022 Oct 19;11(20):6165.

doi: 10.3390/jcm11206165. PMID: 36294486; PMCID: PMC9605111.

- 14: von Deimling M, Rajwa P, Tilki D, Heidenreich A, Pallauf M, Bianchi A, Yanagisawa T, Kawada T, Karakiewicz PI, Gontero P, Pradere B, Ploussard G, Rink M, Shariat SF. The current role of precision surgery in oligometastatic prostate cancer. *ESMO Open*. 2022 Dec;7(6):100597. doi: 10.1016/j.esmoop.2022.100597. Epub 2022 Oct 6. PMID: 36208497; PMCID: PMC9551071.
- 15: Yanagisawa T, Mori K, Quhal F, Kawada T, Mostafaei H, Laukhtina E, Rajwa P, Sari Motlagh R, Aydh A, König F, Pallauf M, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF. Iatrogenic ureteric injury during abdominal or pelvic surgery: a meta-analysis. *BJU Int*. 2022 Oct 5. doi: 10.1111/bju.15913. Epub ahead of print. PMID: 36196670.
- 16: Laukhtina E, Moschini M, Krajewski W, Teoh JY, Ploussard G, Soria F, Roghmann F, Muenker MA, Roumiguie M, Alvarez-Maestro M, Misrai V, Antonelli A, Tafuri A, Simone G, Mastroianni R, Zhao H, Rahota RG, D'Andrea D, Mori K, Albisinni S, Karakiewicz PI, Fajkovic H, Enikeev D, Montorsi F, Shariat SF, Pradere B; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate. *BJU Int*. 2022 Sep 22. doi: 10.1111/bju.15898. Epub ahead of print. PMID: 36134575.
- 17: Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Mostafaei H, Krajewski W, D'Andrea D, Małkiewicz B, Paradysz A, Ploussard G, Moschini M, Breyer BN, Pradere B, Shariat SF, Leapman MS. Online Crowdfunding for Urologic Cancer Care. *Cancers (Basel)*. 2022 Aug 25;14(17):4104. doi: 10.3390/cancers14174104. PMID: 36077641; PMCID: PMC9454944.
- 18: Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, Fukuokaya W, Shim SR, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Pallauf M, Pradere B, Kimura T, Egawa S, Shariat SF. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol*. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19. PMID: 35995644.
- 19: Yanagisawa T, Kawada T, Rajwa P, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, König F, Pallauf M, Pradere B, Karakiewicz PI, Nyirady P, Kimura T, Egawa S, Shariat SF. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis. *Urol Oncol*. 2022 Aug 12:S1078-1439(22)00238-1. doi: 10.1016/j.urolonc.2022.06.018. Epub ahead of print. PMID: 35970698.
- 20: Mori K, Yanagisawa T, Katayama S, Laukhtina E, Pradere B, Mostafaei H, Quhal F, Rajwa P, Moschini M, Soria F, D'andrea D, Abufaraj M, Albisinni S, Krajewski W, Fukuokaya W, Miki J, Kimura T, Egawa S, Teoh JY, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis. *World J Urol*. 2022 Aug 13. doi: 10.1007/s00345-022-04116-x. Epub ahead of print. PMID: 35963957.

- 21: von Deimling M, Pallauf M, Bianchi A, Laukhtina E, Karakiewicz PI, Rink M, Shariat SF, Pradere B. Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity? *Curr Opin Urol.* 2022 Sep 1;32(5):567-574. doi: 10.1097/MOU.0000000000001028. Epub 2022 Jul 22. PMID: 35869738.
- 22: Laukhtina E, Pradere B, Lemberger U, Karakiewicz PI, Fajkovic H, Shariat SF. Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder. *Curr Opin Urol.* 2022 Sep 1;32(5):561-566. doi: 10.1097/MOU.0000000000001013. Epub 2022 Jul 15. PMID: 35849719.
- 23: Pallauf M, König F, D'Andrea D, Laukhtina E, Mostafaei H, Motlagh RS, Quhal F, Aydh A, Yanagisawa T, Kawada T, Rajwa P, Lusuardi L, Soria F, Karakiewicz PI, Rouprêt M, Rink M, Lotan Y, Margulis V, Singla N, Xylinas E, Shariat SF, Pradere B. A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery. *Front Oncol.* 2022 Jul 1;12:907975. doi: 10.3389/fonc.2022.907975. PMID: 35847838; PMCID: PMC9283688.
- 24: D'Andrea D, Shariat SF, Soria F, Mari A, Mertens LS, Di Trapani E, Carrion DM, Pradere B, Pichler R, Filippot R, Grisay G, Del Giudice F, Laukhtina E, Paulnsteiner D, Krajewski W, Vallet S, Maggi M, De Berardinis E, Álvarez-Maestro M, Brönimann S, Di Maida F, van Rhijn BWG, Hendricksen K, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. *Eur Urol Open Sci.* 2022 May 28;41:74-80. doi: 10.1016/j.euros.2022.05.001. PMID: 35813257; PMCID: PMC9257642.
- 25: Stangl-Kremser J, Lambertini L, Di Maida F, Martinez-Fundichely A, Ferro M, Pradere B, Soria F, Albisinni S, Wu Z, Del Giudice F, Cacciamani GE, Valerio M, Briganti A, Rouprêt M, Shariat SF, Lee C, Minervini A, Moschini M, Mari A; European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group. Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines. *Eur Urol Focus.* 2022 Nov;8(6):1622-1626. doi: 10.1016/j.euf.2022.06.004. Epub 2022 Jun 27. PMID: 35773181.
- 26: Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Enei Y, Atsuta M, Mori K, Obayashi K, Yoshihara K, Kondo Y, Oguchi T, Sadakane I, Habuchi T, Ohyama C, Shariat SF, Egawa S. Does castration status affect docetaxel-related adverse events? Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. *Prostate.* 2022 Oct;82(14):1322-1330. doi: 10.1002/pros.24406. Epub 2022 Jun 29. PMID: 35767376.
- 27: Rebhan K, Wasinger G, Hassler MR, Shariat SF, Compérat EM. Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review. *Curr Opin Urol.* 2022 Jul 1;32(4):358-363. doi: 10.1097/MOU.0000000000001007. PMID: 35749783.
- 28: Vartolomei MD, Ferro M, Roth B, Teoh JY, Gontero P, Shariat SF. Device- assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update. *Curr Opin Urol.* 2022 Sep 1; 32(5):575-583. doi: 10.1097/MOU.0000000000001010. Epub 2022 Jun 24. PMID: 35749398.

29: Kawada T, Yanagisawa T, Rajwa P, Sari Motlagh R, Mostafaei H, Quhal F, Laukhtina E, Aydh A, König F, Pallauf M, Pradere B, Ceci F, Baltzer PAT, Hacker M, Rasul S, Karakiewicz PI, Araki M, Nasu Y, Shariat SF.

Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.

Eur Urol Oncol. 2022 Aug; 5(4):390-400.

doi: 10.1016/j.euo.2022.04.006. Epub 2022 Jun 15. PMID: 35715320.

30: Huebner N, Rasul S, Baltzer P, Clauser P, Hermann Grubmüller K, Mitterhauser M, Hacker M, Heidenreich A, Rajwa P, Fajkovic H, Shariat SF, Grubmüller B.

Feasibility and Optimal Time Point of [⁶⁸Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery.

Eur Urol Open Sci. 2022 May 5; 40:117-124.

doi: 10.1016/j.euros.2022.04.003. PMID: 35638090; PMCID: PMC9142741.

31: Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Mori K, Sano T, Otsuka T, Iwamoto Y, Enei Y, Nakazono M, Sakanaka K, Iwatani K, Matsukawa A, Atsuta M, Nishikawa H, Tsuzuki S, Miki J, Habuchi T, Ohyama C, Shariat SF, Egawa S.

Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.

World J Urol. 2022 May 21.

doi: 10.1007/s00345-022-04030-2. Epub ahead of print. PMID: 35596809.

32: Laukhtina E, Boehm A, Peyronnet B, Bravi CA, Batista Da Costa J, Soria F, D'Andrea D, Rajwa P, Quhal F, Yanagisawa T, König F, Mostafaei H, Enikeev D, Ingels A, Verhoest G, D'Hondt F, Mottrie A, Joniau S, Van Poppel H, de la Taille A, Bensalah K, Bruyère F, Shariat SF, Pradere B.

Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.

World J Urol. 2022 Jul;40(7):1689-1696.

doi: 10.1007/s00345-022-04025-z. Epub 2022 May 20. PMID: 35596017; PMCID: PMC9236994.

33: Yanagisawa T, Mori K, Kawada T, Motlagh RS, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF.

Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis.

Urol Oncol. 2022 Jul;40(7):315-330.

doi: 10.1016/j.urolonc.2022.04.002. Epub 2022 May 11. PMID: 35562311.

34: Laukhtina E, Hassler MR, Pradere B, Yanagisawa T, Quhal F, Rajwa P, Sari Motlagh R, König F, Pallauf M, Kawada T, Mostafaei H, D'Andrea D, Enikeev D, Shariat SF.

Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma.

Eur Urol Focus. 2022 Nov;8(6):1683-1686.

doi: 10.1016/j.euf.2022.04.017. Epub 2022 May 11. PMID: 35562252.

35: Aydh A, Motlagh RS, Abufaraj M, Mori K, Katayama S, Grossmann N, Rajwa P, Mostafaei H, Laukhtina E, Pradere B, Quhal F, Schuetthfort VM, Briganti A, Karakiewicz PI, Fajkovic H, Shariat SF.

Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis.

Arab J Urol. 2022 Mar 30;20(2):71-80.

doi: 10.1080/2090598X.2022.2026010. PMID: 35530569; PMCID: PMC9067961.

- 36: Grossmann NC, Rajwa P, Quhal F, König F, Mostafaei H, Laukhtina E, Mori K, Katayama S, Motlagh RS, Fankhauser CD, Mattei A, Moschini M, Chlosta P, van Rhijn BWG, Teoh JYC, Compérat E, Babjuk M, Abufaraj M, Karakiewicz PI, Shariat SF, Pradere B.
Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
Eur Urol Open Sci. 2022 Apr 1;39:14-21.
doi: 10.1016/j.euros.2022.02.011. PMID: 35528782; PMCID: PMC9068727.
- 37: Laukhtina E, Shariat SF.
Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Eur Urol. 2022 Aug; 82(2):242-243.
doi: 10.1016/j.eururo.2022.04.010. Epub 2022 Apr 30. PMID: 35501200.
- 38: Yanagisawa T, Sato S, Hayashida Y, Okada Y, Iwatani K, Matsukawa A, Kimura T, Takahashi H, Egawa S, Shariat SF, Miki J.
Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
BJU Int. 2022 Apr 29.
doi: 10.1111/bju.15760. Epub ahead of print. PMID: 35488409.
- 39: Rajwa P, Pradere B, Gandaglia G, van den Bergh RCN, Tsaur I, Shim SR, Yanagisawa T, Laukhtina E, Mori K, Mostafaei H, Quhal F, Bryniarski P, Compérat E, Roubaud G, Massard C, Merseburger AS, Leapman MS, Spratt DE, Saad F, Joniau S, D'Amico AV, Briganti A, Shariat SF, Ploussard G; European Association of Urology Young Academic Urologists Prostate Cancer Working Party.
Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol. 2022 Jul; 82(1):82-96.
doi: 10.1016/j.eururo.2022.03.031. Epub 2022 Apr 22. PMID: 35465985.
- 40: Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Schmidinger M, Egawa S, Shariat SF.
Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis.
Immunotherapy. 2022 Jun;14(9):709-725.
doi: 10.2217/imt-2021-0207. Epub 2022 Apr 25. PMID: 35465726.
- 41: Sari Motlagh R, Yanagisawa T, Kawada T, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Huebner NA, Baltzer PA, Karakiewicz PI, Heidenreich A, Shariat SF.
Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis.
Prostate Cancer Prostatic Dis. 2022 Feb;25(2):187-198.
doi: 10.1038/s41391-022-00538-1. Epub 2022 Apr 12. PMID: 35414118.
- 42: Mori K, Schuettfort VM, Egawa S, Compérat E, Shariat SF.
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Ann Surg Oncol. 2022 Aug;29(8):5317-5318.
doi: 10.1245/s10434-022-11702-1. Epub 2022 Apr 12. PMID: 35412203; PMCID: PMC9246978.
- 43: König F, Grossmann NC, Soria F, D'Andrea D, Juvet T, Potretzke A, Djaladat H, Ghoreifi A, Kikuchi E, Hayakawa N, Mari A, Khene ZE, Fujita K, Raman JD, Breda A, Fontana M, Sfakianos JP, Pfail JL, Laukhtina E, Rajwa P, Pallauf M, Cacciamani GE, van Doeveren T, Boormans JL, Antonelli A, Jamil M, Abdollah F,

- Budzyn J, Ploussard G, Heidenreich A, Daneshmand S, Boorjian SA, Rouprêt M, Rink M, Shariat SF, Pradere B.
Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics.
Cancers (Basel). 2022 Mar 31;14(7):1781.
doi: 10.3390/cancers14071781. PMID: 35406553; PMCID: PMC8997024.
- 44: Sari Motlagh R, Schuettfort VM, Mori K, Katayama S, Rajwa P, Aydh A, Grossmann NC, Laukhtina E, Pradere B, Mostafai H, Quhal F, Abufaraj M, Lee R, Karakiewicz PI, Lotan Y, Comprate E, Moschini M, Gontero P, Shariat SF.
Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy.
Int J Urol. 2022 Jul;29(7):676-683.
doi: 10.1111/iju.14869. Epub 2022 Apr 2. PMID: 35368130; PMCID: PMC9543826.
- 45: Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Teoh JY, Resch I, Fajkovic H, Moschini M, D'andrea D, Abufaraj M, Karakiewicz PI, Lotan Y, Scherr D, Egawa S, Compérat E, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).
Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
Ann Surg Oncol. 2022 Aug;29(8):5307-5316.
doi: 10.1245/s10434-022-11575-4. Epub 2022 Mar 26. PMID: 35347517; PMCID: PMC9246812.
- 46: Piccinelli ML, Luzzago S, Marvaso G, Laukhtina E, Miura N, Schuettfort VM, Mori K, Colombo A, Ferro M, Mistretta FA, Fusco N, Petralia G, Jerezek-Fossa BA, Shariat SF, Karakiewicz PI, de Cobelli O, Musi G.
Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer.
World J Urol. 2022 Jun;40(6):1447-1454.
doi: 10.1007/s00345-022-03983-8. Epub 2022 Mar 26. PMID: 35347414; PMCID: PMC9166841.
- 47: Mori K, Quhal F, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, Rajwa P, Mostafaei H, Sari Motlagh R, Kimura T, Egawa S, Bensalah K, Karakiewicz PI, Schmidinger M, Shariat SF.
The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis.
Int Immunopharmacol. 2022 Jul;108:108720.
doi: 10.1016/j.intimp.2022.108720. Epub 2022 Mar 24. PMID: 35339843.
- 48: Laukhtina E, Moschini M, Soria F, Andrea DD, Teoh JY, Mori K, Albisinni S, Mari A, Krajewski W, Cimadamore A, Abufaraj M, Enikeev D, Neuzillet Y, Giannarini G, Xylinas E, Kamat AM, Roupert M, Babjuk M, Witjes JA, Shariat SF, Pradere B; European Association of Urology; Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group; European Association of Urology Section of Oncological Urology ESOU.
Follow-up of the Urethra and Management of Urethral Recurrence after Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group.
Eur Urol Focus. 2022 Nov;8(6):1635-1642.
doi: 10.1016/j.euf.2022.03.004. Epub 2022 Mar 23. PMID: 35337773.

- 49: Mori K, Schuettfort VM, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, Rajwa P, Mostafaei H, Sari Motlagh R, Quhal F, Moschini M, Soria F, Teoh JYC, D'Andrea D, Abufaraj M, Albisinni S, Krajewski W, Egawa S, Karakiewicz PI, Rink M, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).
Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2022 Nov;8(6):1687-1695.
doi: 10.1016/j.euf.2022.02.007. Epub 2022 Mar 9. PMID: 35279408.
- 50: Stangl-Kremser J, Muto G, Grosso AA, Briganti A, Comperat E, Di Maida F, Montironi R, Remzi M, Pradere B, Soria F, Albisinni S, Roupret M, Shariat SF, Minervini A, Teoh JY, Moschini M, Cimadamore A, Mari A; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group.
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis.
Urol Oncol. 2022 Jun; 40(6):243-261.
doi: 10.1016/j.urolonc.2022.01.014. Epub 2022 Feb 28. PMID: 35241364.
- 51: Vartolomei L, Cotruș A, Tătaru SO, Vartolomei MD, Man A, Ferro M, Stanciu C, Sin AI, Shariat SF.
Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms.
Aging Male. 2022 Dec;25(1):62-66.
doi: 10.1080/13685538.2022.2040981. PMID: 35179090.
- 52: Katayama S, Mori K, Pradere B, Mostafaei H, Schuettfort VM, Quhal F, Motlagh RS, Laukhtina E, Grossmann NC, Rajwa P, Aydh A, König F, Mathieu R, Nyirady P, Karakiewicz PI, Nasu Y, Shariat SF.
Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis.
Scand J Urol. 2022 Apr;56(2):85-93.
doi: 10.1080/21681805.2022.2034941. Epub 2022 Feb 10. PMID: 35142251.
- 53: Grossmann NC, Pradere B, D'Andrea D, Schuettfort VM, Mori K, Rajwa P, Quhal F, Laukhtina E, Katayama S, Fankhauser CD, Xylinas E, Margulis V, Moschini M, Abufaraj M, Bandini M, Lonati C, Nyirady P, Karakiewicz PI, Fajkovic H, Shariat SF.
Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study.
Clin Genitourin Cancer. 2022 Jun; 20(3):227-236.
doi: 10.1016/j.clgc.2022.01.004. Epub 2022 Jan 11. PMID: 35125303.
- 54: Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists EAU-YAU Urothelial Carcinoma Working Group.
Corrigendum to "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis" [*Eur Urol Oncol* 2021; 4:927-42].
Eur Urol Oncol. 2022 Aug; 5(4):480-481.
doi: 10.1016/j.euo.2022.01.003. Epub 2022 Jan 19.
Erratum for: *Eur Urol Oncol*. 2021 Dec; 4(6):927-942. PMID: 35063436.

- 55: Yanagisawa T, Mori K, Motlagh RS, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, D'Andrea D, Compérat E, Miki J, Kimura T, Egawa S, Shariat SF. En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. *J Urol*. 2022 Apr;207(4):754-768. doi: 10.1097/JU.0000000000002444. Epub 2022 Jan 21. PMID: 35060770.
- 56: Katayama S, Schuettfort VM, Pradere B, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Laukhtina E, Grossmann NC, Aydh A, Rajwa P, König F, Karakiewicz PI, Haydter M, Moschini M, Abufaraj M, Lotan Y, Lee RK, Trinh QD, Compérat E, Teoh J, Nasu Y, Shariat SF. Prognostic value of hepatocyte growth factor for muscle- invasive bladder cancer. *J Cancer Res Clin Oncol*. 2022 Nov;148(11):3091-3102. doi: 10.1007/s00432-021-03887-x. Epub 2022 Jan 8. PMID: 34997350; PMCID: PMC9508199.
- 57: Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Rajwa P, Yanagisawa T, Mostafaei H, König F, Aydh A, Pradere B, Enikeev D, Karakiewicz PI, Schmidinger M, Shariat SF. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. *Eur Urol Oncol*. 2022 Feb;5(1):120-124. doi: 10.1016/j.euo.2021.12.007. Epub 2022 Jan 3. PMID: 34992006.
- 58: Dillinger T, Sheibani-Tezerji R, Pulverer W, Stelzer I, Hassler MR, Scheibelreiter J, Pérez Malla CU, Kuroll M, Domazet S, Redl E, Ely S, Brezina S, Tiefenbacher A, Rebhan K, Hübner N, Grubmüller B, Mitterhauser M, Hacker M, Weinhaeusel A, Simon J, Zeitlinger M, Gsur A, Kramer G, Shariat SF, Kenner L, Egger G. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. *Mol Cancer*. 2022 Jan 3;21(1):7. doi: 10.1186/s12943-021-01445-0. PMID: 34980142; PMCID: PMC8722310.
- 59: Katayama S, Mori K, Pradere B, Yanagisawa T, Mostafaei H, Quhal F, Motlagh RS, Laukhtina E, Grossmann NC, Rajwa P, Aydh A, König F, Karakiewicz PI, Araki M, Nasu Y, Shariat SF. Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. *J Robot Surg*. 2022 Dec;16(6):1233-1247. doi: 10.1007/s11701-021-01361-x. Epub 2021 Dec 31. PMID: 34972981; PMCID: PMC9606098.
- 60: Mostafaei H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, Roehrborn CG, Shariat SF, Hajebrahimi S. The placebo and nocebo effects in functional urology. *Nat Rev Urol*. 2022 Mar;19(3):171-189. doi: 10.1038/s41585-021-00545-2. Epub 2021 Dec 23. PMID: 34949831.
- 61: Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, Shariat SF. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. *Crit Rev Oncol Hematol*. 2022 Jan;169:103570. doi: 10.1016/j.critrevonc.2021.103570. Epub 2021 Dec 10. PMID: 34902554.

62: Grossmann NC, Schuettfort VM, Pradere B, Rajwa P, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Aydh A, Katayama S, Moschini M, Fankhauser CD, Hermanns T, Abufaraj M, Mun DH, Zimmermann K, Fajkovic H, Haydter M, Shariat SF.

Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy.

Urol Oncol. 2022 Mar;40(3):106.e11-106.e19.

doi: 10.1016/j.urolonc.2021.10.006. Epub 2021 Nov 20. PMID: 34810077.

63: Mori K, Katayama S, Laukhtina E, Schuettfort VM, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Zimmermann K, Karakiewicz PI, Abufaraj M, Fajkovic H, Rouprêt M, Margulis V, Enikeev DV, Egawa S, Shariat SF.

Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma.

Clin Genitourin Cancer. 2022 Feb;20(1):95.e1-95.e6.

doi: 10.1016/j.clgc.2021.10.002. Epub 2021 Oct 10. PMID: 34764007.

64: Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Kimura T, Egawa S, Shariat SF.

Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis.

Int J Clin Oncol. 2022 Jan;27(1):59-71.

doi:10.1007/s10147-021-02061-0. Epub 2021 Nov 10. PMID: 34757531; PMCID: PMC8732925.

65: Quhal F, Mori K, Fajkovic H, Remzi M, Shariat SF, Schmidinger M.

Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis.

Curr Opin Urol. 2022 Jan 1;32(1):61-68.

doi: 10.1097/MOU.0000000000000940. PMID: 34720102.

66: Sari Motlagh R, Rajwa P, Mori K, Laukhtina E, Aydh A, Katayama S, Yanagisawa T, König F, Grossmann NC, Pradere B, Mostafai H, Quhal F, Karakiewicz PI, Babjuk M, Shariat SF.

Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources.

J Endourol. 2022 Apr;36(4):535-547.

doi: 10.1089/end.2021.0688. Epub 2021 Nov 16. PMID: 34693740.

67: Luzzago S, Piccinelli ML, Marvaso G, Laukhtina E, Miura N, Schuettfort VM, Mori K, Aydh A, Ferro M, Mistretta FA, Fusco N, Petralia G, Jereczek-Fossa BA, Shariat SF, Karakiewicz PI, de Cobelli O, Musi G.

Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies.

World J Urol. 2022 Feb;40(2):443-451.

doi: 10.1007/s00345-021-03864-6. Epub 2021 Oct 23. PMID: 34687344.

68: Laukhtina E, Schuettfort VM, D'Andrea D, Pradere B, Quhal F, Mori K, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Karakiewicz PI, Schmidinger M, Fajkovic H, Enikeev D, Shariat SF.

Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach.

World J Urol. 2022 Mar;40(3):747-754.

doi: 10.1007/s00345-021-03844-w. Epub 2021 Oct 20. PMID: 34671856; PMCID: PMC8948147.

69: Laukhtina E, Schuettfort VM, D'Andrea D, Pradere B, Mori K, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Zeinler F, Abufaraj M, Moschini M, Zimmermann K, Karakiewicz PI, Fajkovic H, Scherr D, Compérat E, Nyirady P, Rink M, Enikeev D, Shariat SF.

Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.

Mol Carcinog. 2022 Jan;61(1):5-18.

doi: 10.1002/mc.23355. Epub 2021 Sep 29. PMID: 34587660; PMCID: PMC9293216.

70: Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Grossmann NC, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, König F, Roehrborn CG, Katayama S, Rajwa P, Hajebrahimi S, Shariat SF.

Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.

Eur Urol Focus. 2022 Jul;8(4):1072-1089.

doi: 10.1016/j.euf.2021.08.011. Epub 2021 Sep 22. PMID: 34563481.

71: Sari Motlagh R, Abufaraj M, Karakiewicz PI, Rajwa P, Mori K, Mun DH, Shariat SF.

Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.

World J Urol. 2022 Apr;40(4):907-914.

doi: 10.1007/s00345-021-03810-6. Epub 2021 Sep 3. PMID: 34477955; PMCID: PMC8414446.

72: Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, König F, Aydh A, Soria F, Moschini M, Karakiewicz PI, Lotan Y, Scherr D, Haydter M, Nyirady P, Teoh JYC, Egawa S, Compérat E, Shariat SF.

The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.

Eur Urol Focus. 2022 Jul;8(4):972-979.

doi: 10.1016/j.euf.2021.08.006. Epub 2021 Aug 26. PMID: 34454852.

73: Mori K, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Grossmann NC, Rajwa P, Ploussard G, Briganti A, Kimura T, Egawa S, Papalia R, Carrion DM, Fiori C, Shariat SF, Esperto F, Pradere B.

Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile.

Minerva Urol Nephrol. 2022 Jun;74(3):292-301.

doi: 10.23736/S2724-6051.21.04431-1. Epub 2021 Jul 26. PMID: 34308608.

74: Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S, Grossmann NC, Laukhtina E, Mostafaei H, Pradere B, Quhal F, Karakiewicz PI, Enikeev DV, Shariat SF.

The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.

Eur Urol Oncol. 2022 Apr;5(2):138-145.

doi: 10.1016/j.euo.2021.07.002. Epub 2021

Jul 21. PMID: 34301529.

75: Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort VM, Kramer G, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.

Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.

BJU Int. 2022 Apr;129(4):423-433.

doi: 10.1111/bju.15507. Epub 2021 Jul 21. PMID: 34171173; PMCID: PMC9291853.

- 76: Laukhtina E, Rajwa P, Mori K, Moschini M, D'Andrea D, Abufaraj M, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, Shariat SF, Pradere B; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group (EAU YAU). Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. *Eur Urol Focus*. 2022 May; 8(3):752-760. doi: 10.1016/j.euf.2021.05.010. Epub 2021 Jun 12. PMID: 34127436.
- 77: Schuettfort VM, Gust K, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, Shariat SF. Impact of the preoperative modified Glasgow Prognostic Score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. *Minerva Urol Nephrol*. 2022 Jun;74(3):302-312. doi: 10.23736/S2724-6051.21.04216-6. Epub 2021 Jun 11. PMID: 34114784.
- 78: Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Różański W, Soria F, Shariat SF, Fendler W. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer. *Eur Urol Oncol*. 2022 Feb;5(1):109-112. doi: 10.1016/j.euo.2021.05.006. Epub 2021 Jun 3. PMID: 34092528.
- 79: Katayama S, Mori K, Schuettfort VM, Pradere B, Mostafaei H, Quhal F, Rajwa P, Motlagh RS, Laukhtina E, Moschini M, Grossmann NC, Araki M, Teoh JY, Rouprêt M, Margulis V, Enikeev D, Karakiewicz PI, Abufaraj M, Compérat E, Nasu Y, Shariat SF. Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. *Eur Urol Focus*. 2022 May;8(3):761-768. doi: 10.1016/j.euf.2021.05.002. Epub 2021 May 27. PMID: 34053904.
- 80: Schuettfort VM, Pradere B, Trinh QD, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz PI, Chlosta P, Yuen-Chun Teoh J, Lotan Y, Scherr D, Abufaraj M, Moschini M, Shariat SF. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. *Cancer Immunol Immunother*. 2022 Jan;71(1):85-95. doi: 10.1007/s00262-021-02953-0. Epub 2021 May 23. PMID: 34023914; PMCID: PMC8739157.
- 81: Soria F, D'Andrea D, Gontero P, Shariat SF. Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. *Eur Urol Focus* 2020;6:1233-9. *Eur Urol Focus*. 2022 Mar;8(2):633-634. doi: 10.1016/j.euf.2021.04.002. Epub 2021 Apr 17. PMID: 33875390.

82: Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF, Kassouf W.

Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.

Eur Urol Focus. 2022 Mar;8(2):491-497.

doi: 10.1016/j.euf.2021.03.018. Epub 2021 Mar 26. PMID: 33773965.

83: Laukhtina E, Pradere B, D'Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort VM, Enikeev D, Shariat SF.

Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.

Minerva Urol Nephrol. 2022 Jun;74(3):329-336.

doi: 10.23736/S2724-6051.21.04023-6. Epub 2021 Mar 26. PMID: 33769012.

84: Laukhtina E, Abufaraj M, Al-Ani A, Ali MR, Mori K, Moschini M, Quhal F, Sari Motlagh R, Pradere B, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Fajkovic H, Soria F, Enikeev D, Shariat SF; European Association of Urology-Young Academic Urologists (EAU-YAU):

Urothelial carcinoma working group. Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence.

Eur Urol Focus. 2022 Mar;8(2):447-456.

doi: 10.1016/j.euf.2021.03.016. Epub 2021 Mar 21. PMID: 33762203.

85: Mostafaei H, Janisch F, Mori K, Quhal F, Pradere B, Hajebrahimi S, Roehrborn CG, Shariat SF.

Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis.

Eur Urol Focus. 2022 Jan;8(1):239-252.

doi: 10.1016/j.euf.2021.02.005. Epub 2021 Mar 3. PMID: 33674256.

86: Schuettfort VM, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, König F, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, Shariat SF.

A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.

BJU Int. 2022 Feb;129(2):182-193.

doi: 10.1111/bju.15379. Epub 2021 Apr 7. PMID: 33650265; PMCID: PMC9291893.